Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Why Are Karyopharm Shares Plunging Today?

  • Karyopharm Therapeutics Inc (NASDAQ:KPTI) revealed that executive vice president and chief medical officer Jatin Shah departs for "other professional opportunities."
  • While CEO Paulson looks for Shah's replacement, he has recruited two Big Pharma vets to take up key posts on the team: 
    • Patricia Judson, who led women's oncology at GlaxoSmithKline and AstraZeneca, will become the SVP of medical strategy.
    • From AbbVie, Amgen, and Eli Lilly, Stuart Poulton has been appointed SVP of strategy and portfolio management.
  • Karyopharm unveiled Phase 3 results for Xpovio in endometrial cancer, noting the drug cut the risk of disease progression or death by 30% compared to placebo, with median progression-free survival coming in at 5.7 months for the active arm and 3.8 months for the placebo cohort.
  • Price Action: KPTI shares are down 26.80% at $10.52 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.